Last updated on January 2010

Metastatic Colorectal Cancer with wild-type KRAS tumors.

Brief description of study

Metastatic Colorectal Cancer with wild-type KRAS tumors.

Detailed Study Description

Objective response rate, duration of reponse, time to response, time to progression, disease control, overall survival, to evaluate changes in patient-reported outcomes.

Patient Inclusion Criteria:

  • 18 + years
  • Diagnosis of metastatic adenocarcinoma of the colon or rectum that cannot, in the opinon of the investigator, be cured by surgical resection at the time of randomization, wild-type KRAS expressing mCRC tumor, at least one uni-dimensionally measurable lesion

Patient Exclusion Criteria:

  • adiotherapy <14 days before randomization, evidence of central nervous system metastases, history of other invasive primary cancer

Clinical Study Identifier: TX134723

Find a site near you

Start Over

Legacy Pharma Research

601 N. 5th St. Bismarck, ND USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.